FREMONT, Calif., Oct. 24, 2016 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused
on gastrointestinal and cardio-renal diseases, today announced that
Reginald Seeto, MBBS, has joined the
company in the newly created position of chief operating officer.
Dr. Seeto brings over a decade of pharmaceutical industry
experience in corporate development, strategic operations and
global marketing to Ardelyx. His appointment is effective
immediately.
"We could not be more excited about the addition of Reg to our
executive leadership team," said Mike
Raab, president and chief executive officer of Ardelyx. "As
we continue to advance our programs through the clinic, led by the
multiple ongoing Phase 3 studies for tenapanor, and start to
prepare for commercialization, Reg's track record of successfully
introducing new therapies and delivering those therapies to
patients, along with his expertise in corporate development, will
be invaluable to our team. Reg achieved tremendous success in his
years at AstraZeneca and MedImmune, and we look forward to building
upon that success as he integrates into his role at Ardelyx."
Dr. Seeto brings to Ardelyx more than 13 years of experience in
strategic corporate development and senior marketing roles at major
global pharmaceutical companies. Prior to joining the company, he
spent eight years in roles of increasing responsibility at
AstraZeneca and MedImmune, the Biologics Division of AstraZeneca,
most recently serving as vice president, head of partnering and
strategy for AstraZeneca. Earlier, he served as company president
of AstraZeneca Thailand and before that, as executive vice
president of corporate development and strategy for MedImmune.
Prior to joining AstraZeneca/MedImmune, Dr. Seeto held senior
marketing roles at Organon Biosciences, which was acquired by
Schering Plough in 2007, and Boehringer Ingelheim Pharmaceuticals.
Earlier, Dr. Seeto served as an engagement manager for McKinsey
& Company and started his career as a practicing medical doctor
and researcher in Australia. Dr.
Seeto has published several publications in peer-reviewed journals,
including publications focused on his work in gastrointestinal
research. Dr. Seeto earned both his B.S. and MBBS in medical
studies from the University of Sydney,
Australia.
"I am delighted to join the Ardelyx team at such an exciting
time for the company as they progress through the late-stage
clinical development process for tenapanor and look to enter Phase
3 for RDX227675," said Dr. Seeto. "Ardelyx has a seasoned senior
leadership team and an impressive clinical and preclinical
pipeline, which were key drivers in my decision to join the
company. I look forward to helping them bring new GI and
cardio-renal therapies to patients in an area where there are very
limited, effective treatments."
About Ardelyx, Inc.
Ardelyx is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of innovative,
minimally-systemic, small molecule therapeutics that work
exclusively in the gastrointestinal (GI) tract to treat GI and
cardio-renal diseases. Ardelyx has developed a proprietary drug
discovery and design platform enabling it, in a rapid and
cost-efficient manner, to discover and design novel drug
candidates. Utilizing this platform, Ardelyx has discovered and
designed tenapanor, which it is evaluating for the treatment of
irritable bowel syndrome with constipation (IBS-C) and for the
treatment of hyperphosphatemia in patients with end-stage renal
disease (ESRD) on dialysis. In addition to tenapanor, Ardelyx is
developing RDX227675, a non-absorbed polymer for the treatment of
hyperkalemia, or high potassium, a problem prevalent in patients
with kidney and heart disease. Ardelyx is also advancing several
research programs focused in GI and cardio-renal diseases. Ardelyx
is located in Fremont, Calif. For
more information, please visit Ardelyx's website at
www.ardelyx.com.
Logo - http://photos.prnewswire.com/prnh/20140619/119451
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ardelyx-strengthens-executive-leadership-with-the-appointment-of-reginald-seeto-mbbs-as-chief-operating-officer-300349528.html
SOURCE Ardelyx